Kexing Biopharm has secured approval from the European Commission for Apexelsin®, a generic alternative to Abraxane® (nab-paclitaxel) by Bristol Myers Squibb and Celgene. WhiteOak Pharmaceutical B.V. developed Apexelsin®, and Kexing Biopharm will handle its commercialization outside the US.

Apexelsin® utilizes nanoparticle albumin-bound paclitaxel, which offers key benefits over solvent-based and liposomal paclitaxel formulations, including better safety and higher patient compliance. It is well-regarded in oncology and is recommended by the European Society for Medical Oncology (ESMO) for metastatic pancreatic cancer, non-small cell lung cancer (NSCLC), and as a second-line treatment for breast cancer. Given the high incidence of breast cancer among women in the EU, there is substantial demand for effective treatments.

This approval represents a major milestone in Kexing Biopharm's global expansion strategy. The company, which began international operations 20 years ago, has more recently introduced numerous high-quality Chinese medicines to emerging markets, improving patient access. The launch of Apexelsin® in the EU will enhance Kexing Biopharm's competitive edge and expand its global presence, with ongoing efforts to register the product in additional emerging markets. This achievement will enable the company to serve a larger patient and healthcare provider base worldwide.

 

Source: prnewswire.com

Report Abuse